Research Roundup


20191453 - idea concept with light bulbs and energy save bulb green background

Debbie Rigby rounds up the latest in research news 

Triple therapy in the management of chronic obstructive pulmonary disease

A systematic review and meta-analysis of 21 trials shows use of triple therapy resulted in a lower rate of moderate or severe exacerbations of COPD, better lung function, and better health related quality of life than dual therapy or monotherapy in patients with advanced COPD. Pneumonia was significantly higher with triple therapy than with dual therapy of LAMA and LABA. Triple therapy delivered in a single inhaler is non-inferior to the use of multiple inhaler in terms of clinical efficacy.

BMJ 2018;363:k4388.

 

A comprehensive overview on osteoporosis and its risk factors

Multiple risk factors for osteoporosis include advancing age, white race, history of prior fractures and genetic factors. Modifiable factors such as increased alcohol consumption and smoking are also prominent. Furthermore, chronic glucocorticoid use, hypogonadism, diabetes, dementia and RA are secondary causes of osteoporosis discussed in this current review.

Therapeutics and Clinical Risk Management 2018:14 2029–2049.

 

Antibiotics for exacerbations of chronic obstructive pulmonary disease

A Cochrane review has concluded show that currently used antibiotics reduced treatment failures (no improvement in symptoms, despite treatment, within 7 to 28 days, depending on the study) compared with placebo in outpatients with mild to moderate flare-ups, as well as in patients admitted to an intensive care unit for very severe flare-ups with respiratory failure. However, antibiotics did not reduce treatment failures among hospitalised patients with severe flare-ups.

Cochrane Database of Systematic Reviews 2018, Issue 10.

 

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes

A systematic review and meta-analysis of cardiovascular outcome trials has concluded SGLT2i have moderate benefits on atherosclerotic major adverse cardiovascular events that seem confined to patients with established atherosclerotic cardiovascular disease. However, they have robust benefits on reducing hospitalisation for heart failure and progression of renal disease regardless of existing atherosclerotic cardiovascular disease or a history of heart failure.

Lancet, published: November 10, 2018.

 

Previous Seven panel hearings in two months
Next A case of value

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.